Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fera Pharmaceuticals has launched Neptazane (Methazolamide) tablets of strengths 25mg and 50mg in 90 count bottles. Neptazane is suggested in the treatment of ocular conditions where lowering intraocular pressure (IOP) is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
Subscribe to our email newsletter
Methazolamide therapy is contraindicated in situations in which sodium and/or potassium serum levels are depressed, in cases of marked kidney or liver disease or dysfunction, in adrenal gland failure, and in hyperchloremic acidosis.
Additionally, long-term administration of Methazolamide is contraindicated in patients with angle-closure glaucoma, since organic closure of the angle may occur in spite of lowered intraocular pressure.
David Cobb, vice president of ophthalmics for Fera, said: “Neptazane represents an alternative to eye drops when IOP is not effectively controlled or patient compliance becomes an issue.”